Navigation Links
NanoBio Awarded Up To $10 Million In NIH Funding To Develop A Pandemic Influenza Vaccine
Date:10/29/2013

ANN ARBOR, Mich., Oct. 29, 2013 /PRNewswire/ -- NanoBio Corporation today announced that the company has been awarded an initial contract worth $5.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a nanoemulsion (NE) adjuvant for use with a pandemic influenza vaccine. The total contract is valued at approximately $10.5 million, if all options are exercised.

The funding from NIAID will specifically support the research and development of NanoVax®-Panflu, which combines NanoBio's proprietary NE adjuvant with a plant-based recombinant H5 pandemic influenza antigen. This adjuvanted vaccine has the potential to provide enhanced protection against infection by eliciting both mucosal and systemic immunity. Various research efforts have concluded that achieving mucosal immunity is critical for pathogens that enter the body across mucosal surfaces causing respiratory infections and sexually transmitted diseases.

"Our most recent studies at NanoBio have tested NE-adjuvanted vaccines for respiratory syncytial virus (RSV) and type 2 genital herpes (HSV2), two viruses that enter the body via mucosal sites," said David Peralta, chief executive officer of NanoBio. "The results of these studies very clearly demonstrate the ability of the NE adjuvant to elicit mucosal immunity and the important role this type of immunity plays in protecting against disease."

The award includes a future option to test the NE adjuvant with an HIV vaccine. The vaccine will combine NanoBio's NE adjuvant with recombinant HIV virus-like particles. HIV is a global epidemic; the virus is primarily transmitted through sexual contact. A vaccine that elicits mucosal immunity has the potential to minimize transmission of HIV.

Mr. Peralta added, "With this contract support from NIAID, we will further our studies of the NE adjuvant and its important role in enhancing vaccines against challenging respiratory infections and sexually transmitted diseases. We look forward to moving our NanoVax-Panflu vaccine towards the clinic and on the path to commercialization."

NanoBio's NanoStat® technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal, intramuscular or subcutaneous vaccination. In recent studies, NanoBio has demonstrated that intranasal vaccination elicits robust systemic and mucosal immunity, thereby offering enhanced protection against respiratory infections and sexually transmitted diseases compared to intramuscular vaccination.

For additional information, please visit NanoBio.

About NanoBio
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan. For more information on NanoBio or its products, please visit www.nanobio.com.  

Contact:
Schwartz MSL
Stacey Holifield  
NanoBio@SchwartzMSL.com
(781) 684-0770


'/>"/>
SOURCE NanoBio Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
2. Pfenex Inc. awarded a subcontract by Leidos to develop a scalable cGMP production process for a second key malaria antigen
3. AMRI Awarded Development and Manufacture Contract from the UK Government
4. Numotion Awarded Best Complex Rehab Provider
5. Isis Pharmaceuticals Stanley Crooke Awarded Corporate Forums Director of the Year
6. Access Pharmaceuticals Awarded Second European Patent for MuGard
7. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
8. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
9. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
10. Carolina Piedmont Capital Awarded VOSB Certification
11. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)...  Robust competition in the private marketplace is resulting in ... to a new study by the Berkeley ... to examine the share of prescription medicine spending retained ... health plans and other stakeholders in the supply chain. ... show what happens when the list price of a ...
(Date:1/17/2017)... 17, 2017 North America Insulin Delivery Market ... "North America Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... ... , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is ... Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror ... Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
(Date:1/17/2017)... OAKLAND, CA (PRWEB) , ... January 17, 2017 , ... ... been named winners of the fourth Cradle to Cradle Product Design Challenge , ... the fourth in a series of six circular design challenges scheduled to run through ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
Breaking Medicine News(10 mins):